News

2021-04-01

[Conference information] We are joining Cell & Gene Meeting on the Med Virtual from Apr 6-9

Our Advisor, Mr. Russel Gantt and COO Dr. Hidetoshi Hoshiya are joining Cell & Gene Meeting on the Med Virtual. We are looking forward to seeing you at the event.

2021-03-01

Registration is now open; “Dynamic 3D tissue research workshop #4”: Mar.12

We are pleased to announce a series of four online seminars featuring talks by leading researchers in 3D tissue research and the current state of commercialization in start-up companies. We look forward to seeing you at this event.

Fourth session: March 12. 2021, Prof. Takeuchi, the University of Tokyo / HiLung, Inc.

Click here for the event site and registration

2021-02-19

[Conference information] A presentation related to our technology will be given at the 20th Congress of the Japan Society for Regenerative Medicine.

Dr. Kanna Nagaishi of Sapporo Medical University will present her research results using cellfiber technology at the 20th Congress of the Japanese Society for Regenerative Medicine, which will be held from March 11 to 13.

Title: Development of mesenchymal stem cell therapy using cellfiber for inflammatory bowel disease

First author: Dr. Kanna Nagaishi, Associate Professor, Department of Anatomy II, Faculty of Medicine, Sapporo Medical University

Poster “Gastrointestinal tract” P-13-10

Click here for the conference website (fully online)

2021-02-19

[Event information] Career event for UT Healthcare & LifeScience Startups

We will participate in the “the University of Tokyo Healthcare and Life Science Startup Career Fair” with 9 startups from the University of Tokyo.

Date: March 4, 2021, 18:00-19:15

Venue: Online

Click here for event details and application

Nine companies from healthcare and life science startups residing in the University of Tokyo’s incubation facility will gather to talk honestly about their business, the reality of starting a business, the appeal of starting a business, and the human resources they are seeking.
This is an opportunity to make contact with seed and early-stage startups related to the University of Tokyo at once. We look forward to your participation.

2021-02-03

Registration is now open; “Dynamic 3D tissue research workshop #3”: Feb.12

We are pleased to announce a series of four online seminars featuring talks by leading researchers in 3D tissue research and the current state of commercialization in start-up companies. We look forward to seeing you at this event.

Seminar Schedule (tentative)

Third session: February 12. 2021, Assis. Prof. Kato, Nagoya University / Thinkcyte, Inc.

Fourth Session: Mid-March 2021, Prof. Takeuchi, The University of Tokyo, Startup (details will coming soon)

Click here for the event site and registration



2021-01-04

Registration is now open; “Dynamic 3D tissue research workshop #2”: Jan.15

We are pleased to announce a series of four online seminars featuring talks by leading researchers in 3D tissue research and the current state of commercialization in start-up companies. We look forward to seeing you at this event.

Seminar Schedule (tentative)

Second session: Friday, January 15, 2021, Prof. Nagamori, Osaka Institute of Technology / Knowledge Palette Inc.

Third session: Mid-February 2021 Researcher (details will coming soon) / Thinkcyte, Inc.

Fourth Session: Mid-March 2021 Prof. Takeuchi, The University of Tokyo, Startup (details will coming soon)

Click here for the event site and registration



2020-12-29

Hidetoshi Hoshiya has been appointed as a new board director.

Hidetoshi Hoshiya has been appointed as a new board director as of December 1, 2020.

Dr. Hoshiya has more than 15 years of experience in the field of regenerative medicine, cell and gene therapy, having served for more than four years as the manager for Asia and Oceania at the Cell and Gene Therapy Catapult, a regenerative medicine industrialization organization in the UK.
Utilizing Dr. Hoshiya’s experience and knowledge in the industrialization of cell therapy, we will greatly accelerate the clinical application of high production cell culture technology.

Hidetoshi HoshiyaBiography
Graduated from Tottori University in 2009. PhD in Regenerative Medicine, is a Fellow of the Royal Society of Arts and a member of the Royal Society of Biology.
D. in Regenerative Medicine at Tottori University, San Raffaele Scientific Institute (Italy), University College London and Queen Mary University (UK). In November 2019, he became an independent consultant for startups, non-profit organizations, and major pharmaceutical companies. In December 2020, he was appointed to the board of CellFiber. He has more than 15 years of experience in the fields of regenerative medicine, cell and gene therapy.

Comment from Hidetoshi Hoshiya
I believe that CellFiber’s technology has the potential to become the golden standard for mass production of regenerative medical products, including cell and gene therapies. We will do our best to provide highly effective and safe regenerative medical products to patients quickly and inexpensively.

2020-12-15

Representative Director/CAO, Aki Adachi will appear on a online distribution program.

Our Representative Director / CAO, Aki Adachi, will appear on “the SOCIAL” (a news program for online viewing by Nippon Television Network Corporation), which will be broadcasted from noon on December 21, 2020. Please check it out!

the SOCIAL website

2020-12-08

Registration is now open; “Dynamic 3D tissue research workshop”

We are pleased to announce a series of four online seminars featuring talks by leading researchers in 3D tissue research and the current state of commercialization in start-up companies. We look forward to seeing you at this event.

Seminar Schedule (tentative)

First Session: Monday, December 21, 2020, 18:00-19:00 Prof. Onoe, Keio University / CellFiber Co., Ltd.

Second session: Mid-January 2021 Prof. Nagamori, Osaka Institute of Technology / Knowledge Palette Inc.

Third session: Mid-February 2021 Researcher (details will coming soon) / Thinkcyte, Inc.

Fourth Session: Mid-March 2021 Prof. Takeuchi, The University of Tokyo, Startup (details will coming soon)

Click here for the event site and registration

2020-12-08

A collaboration research project with TOYOBO was launched

We have been working on the R&D of high-producing cell culture and material production technologies. We have started joint research with TOYOBO from October 2020. We plan to complete technical evaluations in small-scale trials with several companies and proceed to joint development as needed.

2020-10-14

会社ロゴを刷新しました

セルファイバの新しいロゴを公開しました。

【コンセプト】常に新しい技術や人、要素を取り込み、成長を続ける有機的な組織を表現しました。

【デザイン】セルファイバのコア技術である細胞カプセル化のイメージを取り入れ、中心円を取り囲むように多数の円を配置しました。

【カラー】どんな細胞にも適用できる技術であることから、何色にでも染まる無彩色を採用しました。

2020-10-14

第三者割当による増資を行いました。

 当社は、リアルテックホールディングス株式会社(所在地:東京都墨田区、代表:丸幸弘、永田暁彦)が運営するリアルテックファンドを引受先とした第三者割当増資により、シードラウンドとして1.05億円の資金調達を実施しました。

 今回調達した資金については、主として実験環境の拡充に伴う設備投資、開発加速のための専門人材採用、研究開発に充てる予定です。具体的には2020年10月より実験室面積を2倍に拡張し、間葉系幹細胞及びiPS細胞の培養技術について、実製造へと移行するためスケールアップ、加えて規制への適合に取り組みます。

■問い合わせ先
株式会社セルファイバ:
代表取締役・創業者 安達 亜希(あだち あき)
adachi@cellfiber.jp / 080-5436-0188

リアルテックホールディングス株式会社:
広報担当 成田 真弥(なりた しんや)
contact@realtech.fund

詳細はプレスリリースをご参照ください。

2020-09-03

【9/12開催】LINK-J主催キャリアフォーラムに参加します

LINK-Jが主催するオンラインキャリアイベント「若手研究者のためのスタートアップによるキャリアフォーラム」に参加いたします。

イベント詳細・申し込みはこちら

若手研究者・学生の方を対象に、スタートアップ11社が集うキャリアイベントです。 スタートアップへの進路を考えている方はもちろん、特に就職を考えていない方や在学生の方なども、日頃なかなか出会うことのないスタートアップの事業や雰囲気を体験しにきてください。 皆様のご参加をお待ちしております。

2020-03-13

【3/20開催】HONGO STARTUP MEETUPに参加します

東京大学の学生団体Discovering HONGOが主催するインターンミートアップイベント「HONGO STARTUP MEETUP」に参加いたします。

イベント詳細はこちら

※本イベントの開催にあたっては、新型コロナウイルス感染拡大防止のための政府指針・大学からの要請をふまえ、感染防止対策を行っております。詳細は上記イベントサイトをご参照ください。

2020-03-11

次世代バイオ医薬品製造技術研究組合(MAB)に加入しました

次世代バイオ医薬品製造技術研究組合(Manufacturing Technology Association of Biologics, MAB)に加入しました。

同組合は、次世代バイオ医薬品等の製造に対応するため、我が国の叡智を結集し、国際基準に適合する次世代抗体医薬等の産業技術基盤の確立、および個別化医療に対応した国際ビジネスモデルへの展開を目指しています。

2020-02-12

次世代イノベーション創出プロジェクト2020助成事業に採択されました!

東京都及び公益財団法人 東京都中小企業振興公社が実施する「令和元年度次世代イノベーション創出プロジェクト2020助成事業」の支援対象プロジェクトとして、当社事業「超低コスト再生医療のための細胞培養技術の開発」が採択されました。

細胞治療のコスト削減を目指し、細胞生産技術の確立へ一層のリソースをかけて取り組んでまいります。

2019-03-19

Our website is updated

We updated our website!!